Tirzepatide cuts sleep apnea events
New trial data presented at APhA2026 show tirzepatide (Zepbound) sharply reduced sleep-disordered breathing — the SURMOUNT-OSA study found drops of about 25.3 to 29.3 apnea-hypopnea events per hour versus roughly 5 events/hr with placebo — and patients also saw roughly 17–20% bodyweight loss. (pharmacytimes.com)
Obstructive sleep apnea has usually been treated like a plumbing problem. Airway collapses at night. Breathing stops. A machine pushes air through a mask and props the airway open. That still works. But the SURMOUNT-OSA trial showed something more radical: in adults with obesity and moderate to severe sleep apnea, the obesity drug tirzepatide cut apnea-hypopnea events by about 25 to 29 per hour over 52 weeks, while placebo cut them by only about 5 per hour. The results were strong enough that the FDA approved Zepbound in December 2024 as the first drug specifically indicated for obstructive sleep apnea in adults with obesity (nejm.org; fda.gov). That matters because sleep apnea is not a niche sleep-lab diagnosis. It is one of the most common breathing disorders in medicine, and obesity is one of its main reversible drivers. In SURMOUNT-OSA, researchers enrolled 469 adults without diabetes who had both obesity and moderate to severe sleep apnea. One trial included people who were not using positive airway pressure, or PAP. The other included people already using it. Baseline disease was serious in both groups, with average apnea-hypopnea index scores around 50 events per hour and average body-mass index near 39 (nejm.org; fda.gov). The headline numbers were not subtle. In the trial without PAP, tirzepatide lowered the apnea-hypopnea index by 25.3 events per hour, versus 5.3 with placebo. In the trial with PAP, the drop was 29.3 versus 5.5. Patients also lost a great deal of weight: 17.7% of body weight in one trial and 19.6% in the other, compared with 1.6% and 2.3% on placebo. Those two effects moved together, which is the central fact here. Tirzepatide did not magically relax the throat or replace a CPAP machine. It changed the biology that was helping drive the obstruction in the first place (nejm.org; tctmd.com). That shift showed up in more than one metric. The trial also found improvements in hypoxic burden, blood pressure, inflammation, and patient-reported sleep impairment. A secondary analysis published in Nature Medicine in January 2026 pushed the story further. It found that tirzepatide improved several cardiometabolic risk markers, and mediation analyses suggested the gains were not explained by weight loss alone. Improvements in sleep-disordered breathing itself also appeared to contribute to lower inflammation, better insulin resistance measures, and lower triglycerides (nature.com; nejm.org). The most striking detail is how many people moved out of the worst disease categories. In a 2025 post hoc analysis, 67.7% of tirzepatide-treated participants in the non-PAP study and 79.0% in the PAP study improved to a less severe sleep apnea category by week 52. The share who reached a “no OSA present” category was 24% in one study and 36% in the other. That does not mean sleep apnea has been solved. The drug’s side effects were mostly gastrointestinal, and the FDA still frames its benefit in OSA as likely related to body-weight reduction. But it does mean the field is no longer stuck choosing between masks, surgery, and advice to lose weight somehow. In these trials, a weekly injection moved roughly a quarter to a third of patients all the way to no measurable sleep apnea on the study scale within a year (academic.oup.com; fda.gov).
